골수증식성 질환 치료제 시장 규모, 점유율, 동향 분석 보고서 : 적응증별, 치료 유형별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Myeloproliferative Disorders Drugs Market Size, Share & Trends Analysis Report By Indication (Ph+ Chronic Myelogenous Leukemia (CML)), By Treatment Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,675,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,133,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,049,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

골수증식성 질환 치료제 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 골수증식성 질환 치료제 세계 시장 규모는 2025-2030년까지 연평균 5.9%의 성장률을 기록하며 2030년까지 158억 3,000만 달러에 달할 것으로 예상됩니다. 신약의 가용성, 강력한 파이프라인의 존재, 생활습관 변화로 인한 골수증식성 질환의 발병률 증가, 고령 인구의 증가, 사회적 인식 개선 등이 시장의 주요 성장 촉진요인으로 작용하고 있으며, Jakafi 불내성 환자를 위한 2차 치료제 개발은 Ph-MPN 시장 성장에 유리하게 작용할 것으로 예상됩니다. Ph-MPN 시장에 유리하게 작용할 것으로 추정됩니다.

만성 골수증식성 질환은 말초혈액이나 골수에 성숙 골수세포(적혈구, 과립구, 혈소판)와 그 전구세포(골수구, 메타골수구, 유핵적혈구, 거핵구)가 비정상적으로 축적되는 희귀한 혈액악성질환입니다. 이 분류의 질환에는 크게 4가지 골수증식성 질환이 있으며, 필라델피아 염색체 유무에 따라 더욱 세분화됩니다.

골수증식성 질환은 동아시아 국가에 비해 북미와 서유럽에서 발생률이 높습니다. 대부분의 환자는 60세 이후에 MPN 진단을 받지만, 모든 연령대에서 발병할 수 있습니다. 미국은 골수증식성 질환 치료제의 가장 유력한 시장이며, 그 이유는 대상 인구가 많기 때문입니다.

골수증식성 질환 치료제 시장 보고서 하이라이트

• 북미 골수증식성 질환 치료제 시장은 골수증식성 질환의 높은 유병률과 혁신적인 치료를 지원하는 선진 의료 인프라에 힘입어 2024년 매출 점유율 40.2%로 세계 시장을 석권했습니다.
• 강력한 미충족 수요가 시장의 미래를 형성하고, 획기적인 퍼스트 인 클래스 치료법 개발을 촉진할 것으로 예상됩니다. 미충족 수요가 존재하는 MPNs에서는 Jakafi보다 안전하고, 치료율이 높으며, 알레르기 반응이 적은 약제에 대한 미충족 수요가 존재합니다.
• 주요 시장 진입 기업은 Novartis, Bristol-Myers Squibb, Pfizer, Takeda, Insight, Teva 등입니다. 주요 기업들의 주요 전략은 시장 개척을 위한 제휴와 신흥국 시장에서의 지역 확장입니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 골수증식성 질환 치료제 시장 변수, 동향, 범위

• 시장 계통 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 산업 분석 - Porter's Five Forces 분석
  • PESTLE 분석

제4장 골수증식성 질환 치료제 시장 : 적응증 비즈니스 분석

• 적응증 시장 점유율, 2024년과 2030년
• 적응증 부문 대시보드
• 시장 규모와 예측과 동향 분석, 적응증별, 2018-2030년
• Ph+ 만성 골수성 백혈병(CML)
• Ph- 골수 증식성 종양(MPN)

제5장 골수증식성 질환 치료제 시장 : 치료 유형 비즈니스 분석

• 치료 유형 시장 점유율, 2024년과 2030년
• 치료 유형 부문 대시보드
• 시장 규모와 예측과 동향 분석, 치료 유형별, 2018-2030년
• 화학요법
• 표적요법
• 기타

제6장 골수증식성 질환 치료제 시장 : 최종 용도 비즈니스 분석

• 최종 용도 시장 점유율, 2024년과 2030년
• 최종 용도 부문 대시보드
• 시장 규모와 예측과 동향 분석, 최종 용도별, 2018-2030년
• 병원
• 전문 클리닉
• 기타

제7장 골수증식성 질환 치료제 시장 : 지역별, 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 시장 대시보드
• 시장 규모와 예측 동향 분석, 2018-2030년
• 북미
  • 국가별, 2018-2030년
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 국가별, 2018-2030년
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 덴마크
  • 스웨덴
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 국가별, 2018-2030년
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 국가별, 2018-2030년
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 구도

• 참여자 개요
• 기업의 시장 포지션 분석
• 기업 분류
• 전략 매핑
• 기업 개요/상장 기업
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited.
  • Incyte.
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie Inc.
  • Eli Lilly and Company.
  • GSK plc.
  • GL Pharma

ksm

영문 목차

영문목차

Myeloproliferative Disorders Drugs Market Growth & Trends:

The global myeloproliferative disorders drugs market size is expected to reach USD 15.83 billion by 2030, registering a CAGR of 5.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. Availability of novel drugs, the presence of a strong pipeline, rising incidence of myeloproliferative disorders due to changing lifestyles, growing geriatric population, and increasing public awareness are some of the primary growth stimulants for the market. Therapeutic development in the second-line setting for Jakafi-intolerant patients is estimated to work in favor of the Ph- MPNs market.

Chronic myeloproliferative disorders are rare hematological malignances that involve the abnormal accumulation of mature myeloid cells (red blood cells, granulocytes, and platelets) and their precursors (myelocytes, metamyelocytes, nucleated red blood cells, and megakaryocytes) in the peripheral blood and bone marrow. This class of disorder includes four main myeloproliferative diseases, which are further categorized by the presence of the Philadelphia chromosome.

There is a higher incidence of myeloproliferative disorders in North America and Western Europe as compared to East-Asian countries. Most patients are diagnosed with MPNs after 60 years of age, however, the diseases can occur in any age group. The U.S. will be the most prominent market for myeloproliferative disorders drugs owing to the presence of a large target population.

Myeloproliferative Disorders Drugs Market Report Highlights:

• North America myeloproliferative disorders drugs market dominated the global market with a revenue share of 40.2% in 2024, driven by high prevalence rates of myeloproliferative disorders coupled with advanced healthcare infrastructure that supports innovative treatments.
• Strong unmet needs are likely to shape the future of the market and encourage the development of breakthrough first-in-class therapies. Opportunities remain in the Ph- MPNs setting where there exists an unmet need for a safer drug than Jakafi with higher cure rates and lesser allergic effects
• Some of the key market participants are Novartis, Bristol-Myers Squibb, Pfizer, Takeda, Incyte, and Teva. Primary go-to strategies of prominent players include collaborations for the development and regional expansion in emerging markets.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Indication
  • 1.2.2. Treatment Type
  • 1.2.3. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Myeloproliferative Disorders Drugs Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Myeloproliferative Disorders Drugs Market: Indication Business Analysis

• 4.1. Indication Market Share, 2024 & 2030
• 4.2. Indication Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Billion)
• 4.4. Ph+ Chronic Myelogenous Leukemia (CML)
  • 4.4.1. Ph+ Chronic Myelogenous Leukemia (CML) Market, 2018 - 2030 (USD Billion)
• 4.5. Ph- Myeloproliferative Neoplasms (MPNs)
  • 4.5.1. Ph- Myeloproliferative Neoplasms (MPNs) Market, 2018 - 2030 (USD Billion)
  • 4.5.2. Myelofibrosis (MF)
  • 4.5.3. Myelofibrosis (MF) Market, 2018 - 2030 (USD Billion)
  • 4.5.4. Polycythemia Vera (PV)
  • 4.5.5. Polycythemia Vera (PV) Market, 2018 - 2030 (USD Billion)
  • 4.5.6. Essential Thrombocythemia (ET)
  • 4.5.7. Essential Thrombocythemia (ET) Market, 2018 - 2030 (USD Billion)

Chapter 5. Myeloproliferative Disorders Drugs Market: Treatment Type Business Analysis

• 5.1. Treatment Type Market Share, 2024 & 2030
• 5.2. Treatment Type Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Treatment Type, 2018 to 2030 (USD Billion)
• 5.4. Chemotherapy
  • 5.4.1. Chemotherapy Market, 2018 - 2030 (USD Billion)
• 5.5. Targeted Therapy
  • 5.5.1. Targeted Therapy Market, 2018 - 2030 (USD Billion)
• 5.6. Others
  • 5.6.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 6. Myeloproliferative Disorders Drugs Market: End Use Business Analysis

• 6.1. End Use Market Share, 2024 & 2030
• 6.2. End Use Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Billion)
• 6.4. Hospitals
  • 6.4.1. Hospitals Market, 2018 - 2030 (USD Billion)
• 6.5. Specialty Clinics
  • 6.5.1. Specialty Clinics Market, 2018 - 2030 (USD Billion)
• 6.6. Others
  • 6.6.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 7. Myeloproliferative Disorders Drugs Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America Myeloproliferative Disorders Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Regulatory Framework
    • 7.4.2.3. Competitive Insights
    • 7.4.2.4. U.S. Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Regulatory Framework
    • 7.4.3.3. Competitive Insights
    • 7.4.3.4. Canada Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Regulatory Framework
    • 7.4.4.3. Competitive Insights
    • 7.4.4.4. Mexico Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.5. Europe
  • 7.5.1. Europe Myeloproliferative Disorders Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory Framework
    • 7.5.2.3. Competitive Insights
    • 7.5.2.4. UK Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Regulatory Framework
    • 7.5.3.3. Competitive Insights
    • 7.5.3.4. Germany Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Regulatory Framework
    • 7.5.4.3. Competitive Insights
    • 7.5.4.4. France Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Regulatory Framework
    • 7.5.5.3. Competitive Insights
    • 7.5.5.4. Italy Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Regulatory Framework
    • 7.5.6.3. Competitive Insights
    • 7.5.6.4. Spain Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.7. Norway
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Regulatory Framework
    • 7.5.7.3. Competitive Insights
    • 7.5.7.4. Norway Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.8. Denmark
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Regulatory Framework
    • 7.5.8.3. Competitive Insights
    • 7.5.8.4. Denmark Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.9. Sweden
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Regulatory Framework
    • 7.5.9.3. Competitive Insights
    • 7.5.9.4. Sweden Myeloproliferative Disorders Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory Framework
    • 7.6.2.3. Competitive Insights
    • 7.6.2.4. Japan Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Regulatory Framework
    • 7.6.3.3. Competitive Insights
    • 7.6.3.4. China Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Regulatory Framework
    • 7.6.4.3. Competitive Insights
    • 7.6.4.4. India Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.5. South Korea
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Regulatory Framework
    • 7.6.5.3. Competitive Insights
    • 7.6.5.4. South Korea Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.6. Australia
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Regulatory Framework
    • 7.6.6.3. Competitive Insights
    • 7.6.6.4. Australia Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Regulatory Framework
    • 7.6.7.3. Competitive Insights
    • 7.6.7.4. Thailand Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.7. Latin America
  • 7.7.1. Latin America Myeloproliferative Disorders Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Regulatory Framework
    • 7.7.2.3. Competitive Insights
    • 7.7.2.4. Brazil Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Regulatory Framework
    • 7.7.3.3. Competitive Insights
    • 7.7.3.4. Argentina Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.8. MEA
  • 7.8.1. MEA Myeloproliferative Disorders Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Regulatory Framework
    • 7.8.2.3. Competitive Insights
    • 7.8.2.4. South Africa Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Regulatory Framework
    • 7.8.3.3. Competitive Insights
    • 7.8.3.4. Saudi Arabia Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Regulatory Framework
    • 7.8.4.3. Competitive Insights
    • 7.8.4.4. UAE Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Regulatory Framework
    • 7.8.5.3. Competitive Insights
    • 7.8.5.4. Kuwait Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Novartis AG
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Bristol-Myers Squibb Company
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Pfizer Inc.
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Takeda Pharmaceutical Company Limited.
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Incyte.
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Teva Pharmaceutical Industries Ltd.
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. AbbVie Inc.
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Eli Lilly and Company.
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. GSK plc.
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. GL Pharma
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives

관련자료